Background
Hypokalemia is of clinical relevance in cattle. Different mostly empirical treatment options are suggested.
Hypothesis/Objectives
To evaluate if oral administration of potassium influences the plasma concentration, the intracellular concentration in erythrocytes and in muscle, renal excretion of potassium, and to assess if there are differences in the efficacy of the potassium formulations.
Animals
Thirty cows with hypokalemia (plasma concentration <3.5 mmol/L) were systematically allocated to 3 treatment groups (10 cows/group).
Methods
The cows received 52 g of potassium in different formulations: group B—potassium chloride bolus (release over 12 hours); group G—potassium propionate gel (release over 2 hours); and group S—potassium chloride solution (immediately available). Potassium concentrations were repeatedly measured in plasma, erythrocytes, muscle, and urine using ICP‐OES.
Results
Plasma potassium concentrations for all preparations increased within 30 minutes and the increase lasted for 12 hours. The concentrations of potassium in the erythrocytes and in the muscle, renal potassium excretion, and total urine volume were not affected by administration of any product. There were no differences between the treatments groups. The feed intake increased in 50% of cows within 2 hours after potassium application, which may contribute to the increase of plasma potassium concentration.
Conclusions and Clinical Importance
All the studied potassium formulations are equally effective to treat hypokalemia in dairy cows for over 12 hours but do not influence intracellular concentration or renal excretion of potassium. The plasma potassium concentration should be reevaluated after 12 hours.
Background and aim: Patients with advanced colorectal cancer (mCRC) are commonly treated with systemic treatment consisting of fluoropyrimidine-based regimens being ineffective in 20-25% of the patients. Currently, selection criteria for patients to predict who will respond to this treatment is lacking. The aim of this study is to identify which patients will respond to first line fluoropyrimidine-based treatment based using microRNA (miR) expression profiles in order to avoid ineffective treatment.
Material and methods: Total RNA was isolated from 88 fresh frozen colorectal cancer tissue samples consisting of ≥ 70% tumor cells, collected from patients with mCRC. MiR expression profiles were generated by next generation sequencing using the Illumina High Seq 2000 platform. Of all patients clinical and pathological data, including treatment response based on RECIST criteria, were collected. Class prediction and miR selection were performed using the GRidge package in R. Penalized selection and internal cross validation were used to select miRs predictive for treatment response.
RESULTS: Next generation sequencing resulted in a mean of 10.087.107 (range 6.114.932 to 74.313.067) reads per sample corresponding to 2567 unique mature miR sequences, including 457 novel candidate and 2110 known miRs sequences (miRbase version 19). Penalized regression analysis on tumor specific miRs identified an expression profile which was predictive for clinical benefit (defined as response and stable disease) from first line treatment.
Conclusion: With miR profiling of CRC tissue samples response prediction to first line fluoropyrimidine-based treatment in patients with mCRC is possible. We foresee that selection of treatment using miR expression profiling will avoid unnecessary treatment related toxicity and improve outcome for patients with mCRC
Citation Format: Dennis Poel, Maarten Neerincx, Daoud L.S. Sie, Nicole C.T. van Grieken, R Shankaraiah, F. S.W. van der Wolf, J. H.T.M van Waesberghe, J. D. Burggraaf, Paul P. Eijk, Bauke Ylstra, Cees Verhoef, Mark A. van de Wiel, Henk M.W. Verheul, Tineke E. Buffart. MiR expression profiles can predict response to systemic treatment in patients with advanced colorectal cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4928.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.